BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Pittsburgh Life Sciences Greenhouse Incubator Signs Nurel Therapeutics, Inc. As New Tenant


10/19/2005 5:10:51 PM

PITTSBURGH, Aug. 17 /PRNewswire/ -- The Pittsburgh Life Sciences Greenhouse (PLSG), a partnership to put the region's life sciences industry on a fast track for growth, today announced that Nurel Therapeutics, Inc., has leased laboratory space in the PLSG Incubator.

Nurel Therapeutics is a specialty biotechnology company developing products to treat and manage pain and peripheral nerve damage, and is expanding into vascular disease. The company's products use a proprietary drug-delivery technology derived from an "inert" herpes simplex virus that provides gene-based medicine in a safe and effective manner.

"Nurel has raised some initial funds to help develop our first product candidate, NPE1, a treatment for chronic pain that has a potential market of $1 billion in the United States," said Frank Tufaro, Ph.D., Nurel's founder, President and Chief Executive Officer. "We are very encouraged by the amount of support we are receiving, particularly from the Pittsburgh Life Sciences Greenhouse."

"The PLSG Incubator will provide Nurel with the working environment it needs to take its initial product into Phase One clinical studies and hopefully a dynamic phase of growth for the company," said Doros Platika, M.D. PLSG Chief Executive Officer. "The PLSG is confident that Nurel Therapeutics and others like it will continue to shape a strong and prosperous life sciences community in the region, improving the quality of medical care, creating good jobs and saving lives."

About the PLSG Incubator

The PLSG Incubator is co-located with the PLSG administrative and support functions, which together occupy 17,000 square feet of space on the fourth floor of Bridgeside Point, better known as the Cellomics Building on Technology Drive in Pittsburgh. Incubator facilities consist of 40 percent lab and 60 percent office space and houses 13 life sciences organizations, which also have convenient access to other services programs offered by the PLSG.

About the PLSG

The Pittsburgh Life Sciences Greenhouse is a public/private partnership, founded by the University of Pittsburgh, Carnegie Mellon University, UPMC Health System, the Commonwealth of Pennsylvania and its regional foundation community. Together with private industry and advanced research and healthcare capabilities of our institutional partners, PLSG invests in and supports the growth of regional life sciences companies in the areas of: bioinformatics; bionanotechnology; diagnostics; medical devices; medical robotics; therapeutics; and tools and services. These companies are focused in the following sectors: drug discovery tools and targets, biomedical devices, tissue engineering and neurological/psychiatric strategy companies.

Pittsburgh Life Sciences Greenhouse (PLSG)

CONTACT: Tim O'Brien of O'Brien Communications, +1-412-854-8845; or LynnBanaszak of Pittsburgh Life Sciences Greenhouse, +1-412-770-1353; or FrankTufara of Nurel Therapeutics, +1-858-342-6577



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES